AA
NTLA icon

ALPS Advisors’s Intellia Therapeutics NTLA Stock Holding History

ALPS Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77,328
Closed -$550K – 1050
2025
Q1 		$550K Sell
77,328
-5,030
-6% -$50.8K ﹤0.01% 578
2024
Q4 		$960K Buy
82,358
+6,147
+8% +$95.9K 0.01% 486
2024
Q3 		$1.57M Buy
76,211
+974
+1% +$22.5K 0.01% 395
2024
Q2 		$1.68M Buy
75,237
+7,455
+11% +$178K 0.01% 366
2024
Q1 		$1.86M Buy
67,782
+5,487
+9% +$152K 0.01% 364
2023
Q4 		$1.9M Buy
+62,295
New +$1.79M 0.01% 337
2022
Q4 		– Sell
-41,521
Closed -$2.32M – 1072
2022
Q3 		$2.32M Sell
41,521
-3,479
-8% -$216K 0.02% 284
2022
Q2 		$2.33M Buy
+45,000
New +$2.29M 0.02% 288

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ALPS Advisors's NTLA Position: Q2 2025 in Review

ALPS Advisors sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 77,328 shares — an estimated $550K sold.

ALPS Advisors first reported a position in NTLA in Q2 2022 and held it in 8 quarters. The position peaked at $2.33M in Q2 2022. 280 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

  • ALPS Advisors reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ALPS Advisors sold 77,328 Intellia Therapeutics shares in Q2 2025, an estimated $550K.
  • ALPS Advisors first reported a position in Intellia Therapeutics in Q2 2022 and held it in 8 quarters.
  • ALPS Advisors's Intellia Therapeutics position peaked at $2.33M in Q2 2022.
  • 280 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.